BioCentury
ARTICLE | Emerging Company Profile

Triplet debuts with $59M, therapies for repeat expansion disorders

Triplet aims to treat repeat expansion disorders by targeting the DNA damage response pathway

December 17, 2019 11:30 AM UTC
Updated on Dec 17, 2019 at 11:14 PM UTC


Access this Article

BCIQ Company Profiles

Atlas Venture

Korro Bio Inc.